
LINK . SPRINGER . COM {
}
Title:
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results | Journal for ImmunoTherapy of Cancer
Description:
AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. # NCT00678119
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Education
- Science
- Health & Fitness
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We're unsure how the site profits.
Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.
Keywords {🔍}
patients, ags, pubmed, sunitinib, study, article, risk, cell, google, scholar, survival, cells, treatment, cas, cancer, response, renal, intermediate, tumor, clinical, carcinoma, poor, mrcc, immunotherapy, metastatic, months, ctls, therapy, rcc, phase, number, events, immune, time, rna, responses, median, dose, autologous, targeted, analysis, dcs, patient, prior, central, clin, data, dendritic, combination, adverse,
Topics {✒️}
multi-color flow cytometry metastatic renal-cell carcinoma functional cd28+/cd45ra- ctls/ml rna encoding cd40l tumor antigen-specific stimulating cell-mediated immunity myeloid cell-mediated immunosuppression full size image matured monocyte-derived dcs patient-specific tumor antigens renal cell carcinoma functional cd28+/cd45ra- ctls cd8+ t-cell memory article download pdf cd8 t-cell population myeloid-derived suppressor cells patient-specific immunotherapeutic product rna-loaded mature dcs therapy-specific response criteria track t-cell proliferation rna-transfected dendritic cells /1 μg/ml prostaglandin e2 motzer rj cytotoxic t-cell responses cr + pr + stable disease [sd] renal cell cancer anti-angiogenic agent combined identify cd28+/cd45ra- cd8 + localized injection-site reactions tumor-reactive ctls prior early-stage colorectal cancer vaccine-mediated antitumor immunity clear cell mrcc generate anti-tumor memory multiplex rt-pcr amplification tumor micro-environment observed kaplan-meier pfs estimates mild injection-site reactions dendritic-cell immunotherapy decreases t-regulatory cells open access license vascular endothelial growth small number multiple target antigens frequent ags-003-related events autologous tumor rna effector memory ctls kaplan-meier os estimates published randomised trials induced ctl response
Questions {❓}
- Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?
Schema {🗺️}
WebPage:
mainEntity:
headline:Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
description:AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. #
NCT00678119
datePublished:2015-04-21T00:00:00Z
dateModified:2015-04-21T00:00:00Z
pageStart:1
pageEnd:13
license:http://creativecommons.org/publicdomain/zero/1.0/
sameAs:https://doi.org/10.1186/s40425-015-0055-3
keywords:
Immunotherapy
Dendritic cell
RCC
AGS-003
Sunitinib
Oncology
Immunology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig1_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig4_HTML.gif
isPartOf:
name:Journal for ImmunoTherapy of Cancer
issn:
2051-1426
volumeNumber:3
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Asim Amin
affiliation:
name:Levine Cancer Institute
address:
name:Levine Cancer Institute, Charlotte, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Arkadiusz Z Dudek
affiliation:
name:University of Illinois Cancer Center
address:
name:University of Illinois Cancer Center, Chicago, USA
type:PostalAddress
type:Organization
type:Person
name:Theodore F Logan
affiliation:
name:Indiana University Simon Cancer Center
address:
name:Indiana University Simon Cancer Center, Indianapolis, USA
type:PostalAddress
type:Organization
type:Person
name:Raymond S Lance
affiliation:
name:Urology of Virginia
address:
name:Urology of Virginia, Norfolk, USA
type:PostalAddress
type:Organization
type:Person
name:Jeffrey M Holzbeierlein
affiliation:
name:University of Kansas Medical Center
address:
name:University of Kansas Medical Center, Kansas City, USA
type:PostalAddress
type:Organization
type:Person
name:Jennifer J Knox
affiliation:
name:Princess Margaret Hospital
address:
name:Princess Margaret Hospital, Toronto, Canada
type:PostalAddress
type:Organization
type:Person
name:Viraj A Master
affiliation:
name:Emory University
address:
name:Emory University, Atlanta, USA
type:PostalAddress
type:Organization
type:Person
name:Sumanta K Pal
affiliation:
name:City of Hope Comprehensive Cancer Center
address:
name:City of Hope Comprehensive Cancer Center, Duarte, USA
type:PostalAddress
type:Organization
type:Person
name:Wilson H Miller
affiliation:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
address:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
type:PostalAddress
type:Organization
type:Person
name:Lawrence I Karsh
affiliation:
name:The Urology Center of Colorado
address:
name:The Urology Center of Colorado, Denver, USA
type:PostalAddress
type:Organization
type:Person
name:Irina Y Tcherepanova
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Mark A DeBenedette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:W Lee Williams
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Douglas C Plessinger
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Charles A Nicolette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Robert A Figlin
affiliation:
name:Cedars-Sinai Medical Center
address:
name:Cedars-Sinai Medical Center, Los Angeles, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
description:AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. #
NCT00678119
datePublished:2015-04-21T00:00:00Z
dateModified:2015-04-21T00:00:00Z
pageStart:1
pageEnd:13
license:http://creativecommons.org/publicdomain/zero/1.0/
sameAs:https://doi.org/10.1186/s40425-015-0055-3
keywords:
Immunotherapy
Dendritic cell
RCC
AGS-003
Sunitinib
Oncology
Immunology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig1_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig4_HTML.gif
isPartOf:
name:Journal for ImmunoTherapy of Cancer
issn:
2051-1426
volumeNumber:3
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Asim Amin
affiliation:
name:Levine Cancer Institute
address:
name:Levine Cancer Institute, Charlotte, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Arkadiusz Z Dudek
affiliation:
name:University of Illinois Cancer Center
address:
name:University of Illinois Cancer Center, Chicago, USA
type:PostalAddress
type:Organization
type:Person
name:Theodore F Logan
affiliation:
name:Indiana University Simon Cancer Center
address:
name:Indiana University Simon Cancer Center, Indianapolis, USA
type:PostalAddress
type:Organization
type:Person
name:Raymond S Lance
affiliation:
name:Urology of Virginia
address:
name:Urology of Virginia, Norfolk, USA
type:PostalAddress
type:Organization
type:Person
name:Jeffrey M Holzbeierlein
affiliation:
name:University of Kansas Medical Center
address:
name:University of Kansas Medical Center, Kansas City, USA
type:PostalAddress
type:Organization
type:Person
name:Jennifer J Knox
affiliation:
name:Princess Margaret Hospital
address:
name:Princess Margaret Hospital, Toronto, Canada
type:PostalAddress
type:Organization
type:Person
name:Viraj A Master
affiliation:
name:Emory University
address:
name:Emory University, Atlanta, USA
type:PostalAddress
type:Organization
type:Person
name:Sumanta K Pal
affiliation:
name:City of Hope Comprehensive Cancer Center
address:
name:City of Hope Comprehensive Cancer Center, Duarte, USA
type:PostalAddress
type:Organization
type:Person
name:Wilson H Miller
affiliation:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
address:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
type:PostalAddress
type:Organization
type:Person
name:Lawrence I Karsh
affiliation:
name:The Urology Center of Colorado
address:
name:The Urology Center of Colorado, Denver, USA
type:PostalAddress
type:Organization
type:Person
name:Irina Y Tcherepanova
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Mark A DeBenedette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:W Lee Williams
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Douglas C Plessinger
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Charles A Nicolette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
type:Person
name:Robert A Figlin
affiliation:
name:Cedars-Sinai Medical Center
address:
name:Cedars-Sinai Medical Center, Los Angeles, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Journal for ImmunoTherapy of Cancer
issn:
2051-1426
volumeNumber:3
Organization:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Levine Cancer Institute
address:
name:Levine Cancer Institute, Charlotte, USA
type:PostalAddress
name:University of Illinois Cancer Center
address:
name:University of Illinois Cancer Center, Chicago, USA
type:PostalAddress
name:Indiana University Simon Cancer Center
address:
name:Indiana University Simon Cancer Center, Indianapolis, USA
type:PostalAddress
name:Urology of Virginia
address:
name:Urology of Virginia, Norfolk, USA
type:PostalAddress
name:University of Kansas Medical Center
address:
name:University of Kansas Medical Center, Kansas City, USA
type:PostalAddress
name:Princess Margaret Hospital
address:
name:Princess Margaret Hospital, Toronto, Canada
type:PostalAddress
name:Emory University
address:
name:Emory University, Atlanta, USA
type:PostalAddress
name:City of Hope Comprehensive Cancer Center
address:
name:City of Hope Comprehensive Cancer Center, Duarte, USA
type:PostalAddress
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
address:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
type:PostalAddress
name:The Urology Center of Colorado
address:
name:The Urology Center of Colorado, Denver, USA
type:PostalAddress
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
name:Cedars-Sinai Medical Center
address:
name:Cedars-Sinai Medical Center, Los Angeles, USA
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Asim Amin
affiliation:
name:Levine Cancer Institute
address:
name:Levine Cancer Institute, Charlotte, USA
type:PostalAddress
type:Organization
email:[email protected]
name:Arkadiusz Z Dudek
affiliation:
name:University of Illinois Cancer Center
address:
name:University of Illinois Cancer Center, Chicago, USA
type:PostalAddress
type:Organization
name:Theodore F Logan
affiliation:
name:Indiana University Simon Cancer Center
address:
name:Indiana University Simon Cancer Center, Indianapolis, USA
type:PostalAddress
type:Organization
name:Raymond S Lance
affiliation:
name:Urology of Virginia
address:
name:Urology of Virginia, Norfolk, USA
type:PostalAddress
type:Organization
name:Jeffrey M Holzbeierlein
affiliation:
name:University of Kansas Medical Center
address:
name:University of Kansas Medical Center, Kansas City, USA
type:PostalAddress
type:Organization
name:Jennifer J Knox
affiliation:
name:Princess Margaret Hospital
address:
name:Princess Margaret Hospital, Toronto, Canada
type:PostalAddress
type:Organization
name:Viraj A Master
affiliation:
name:Emory University
address:
name:Emory University, Atlanta, USA
type:PostalAddress
type:Organization
name:Sumanta K Pal
affiliation:
name:City of Hope Comprehensive Cancer Center
address:
name:City of Hope Comprehensive Cancer Center, Duarte, USA
type:PostalAddress
type:Organization
name:Wilson H Miller
affiliation:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
address:
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
type:PostalAddress
type:Organization
name:Lawrence I Karsh
affiliation:
name:The Urology Center of Colorado
address:
name:The Urology Center of Colorado, Denver, USA
type:PostalAddress
type:Organization
name:Irina Y Tcherepanova
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
name:Mark A DeBenedette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
name:W Lee Williams
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
name:Douglas C Plessinger
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
name:Charles A Nicolette
affiliation:
name:Argos Therapeutics, Inc.
address:
name:Argos Therapeutics, Inc., Durham, USA
type:PostalAddress
type:Organization
name:Robert A Figlin
affiliation:
name:Cedars-Sinai Medical Center
address:
name:Cedars-Sinai Medical Center, Los Angeles, USA
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Levine Cancer Institute, Charlotte, USA
name:University of Illinois Cancer Center, Chicago, USA
name:Indiana University Simon Cancer Center, Indianapolis, USA
name:Urology of Virginia, Norfolk, USA
name:University of Kansas Medical Center, Kansas City, USA
name:Princess Margaret Hospital, Toronto, Canada
name:Emory University, Atlanta, USA
name:City of Hope Comprehensive Cancer Center, Duarte, USA
name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
name:The Urology Center of Colorado, Denver, USA
name:Argos Therapeutics, Inc., Durham, USA
name:Argos Therapeutics, Inc., Durham, USA
name:Argos Therapeutics, Inc., Durham, USA
name:Argos Therapeutics, Inc., Durham, USA
name:Argos Therapeutics, Inc., Durham, USA
name:Cedars-Sinai Medical Center, Los Angeles, USA
External Links {🔗}(201)
- What's the financial gain of https://www.springernature.com/gp/authors?
- Explore the financials of https://link.springernature.com/home/
- How much does https://order.springer.com/public/cart gross monthly?
- What's the total monthly financial gain of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- How much does https://clinicaltrials.gov/ct2/show/NCT00678119 pull in monthly?
- Revenue of https://doi.org/10.1097%2FCCO.0b013e328351c646
- Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22343386 earns monthly
- How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471654 generate?
- How much does http://scholar.google.com/scholar_lookup?&title=Targeted%20therapeutic%20strategies%20for%20the%20management%20of%20renal%20cell%20carcinoma&journal=Curr%20Opin%20Oncol&doi=10.1097%2FCCO.0b013e328351c646&volume=24&issue=3&pages=284-290&publication_year=2012&author=Singer%2CEA&author=Gupta%2CGN&author=Srinivasan%2CR generate monthly?
- How much does https://doi.org/10.1111%2Fj.1464-410X.2011.10629.x bring in each month?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21952069?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Targeted%20therapy%20for%20advanced%20renal%20cell%20cancer%20%28RCC%29%3A%20a%20Cochrane%20systematic%20review%20of%20published%20randomised%20trials&journal=BJU%20Int&doi=10.1111%2Fj.1464-410X.2011.10629.x&volume=108&issue=10&pages=1556-1563&publication_year=2011&author=Coppin%2CC&author=Kollmannsberger%2CC&author=Le%2CL&author=Porzsolt%2CF&author=Wilt%2CTJ
- What's the income generated by https://doi.org/10.1200%2FJCO.2011.37.2516 each month?
- What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22231040?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Complete%20remission%20with%20tyrosine%20kinase%20inhibitors%20in%20renal%20cell%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2011.37.2516&volume=30&issue=5&pages=482-487&publication_year=2012&author=Albiges%2CL&author=Oudard%2CS&author=Negrier%2CS&author=Caty%2CA&author=Gravis%2CG&author=Joly%2CF&author=Duclos%2CB&author=Geoffrois%2CL&author=Rolland%2CF&author=Guillot%2CA&author=Laguerre%2CB&author=Legouffe%2CE&author=Kohser%2CF&author=Dietrich%2CPY&author=Theodore%2CCA&author=Escudier%2CB
- Learn how profitable https://doi.org/10.1038%2Fsj.bjc.6606084 is on a monthly basis
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21285971
- What's the income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049574?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Challenges%20and%20opportunities%20for%20converting%20renal%20cell%20carcinoma%20into%20a%20chronic%20disease%20with%20targeted%20therapies&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6606084&volume=104&issue=3&pages=399-406&publication_year=2011&author=Gore%2CME&author=Larkin%2CJM
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21917625 income
- How much income does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020430 have?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Role%20of%20immunotherapy%20for%20renal%20cell%20cancer%20in%202011&journal=J%20Natl%20Compr%20Canc%20Netw&volume=9&issue=9&pages=1011-1018&publication_year=2011&author=George%2CS&author=Pili%2CR&author=Carducci%2CMA&author=Kim%2CJJ have monthly?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19165638 generate?
- How much does http://scholar.google.com/scholar_lookup?&title=Treatment%20selection%20for%20patients%20with%20metastatic%20renal%20cell%20carcinoma%3A%20identification%20of%20features%20favoring%20upfront%20IL-2-based%20immunotherapy&journal=Med%20Oncol&doi=10.1007%2Fs12032-008-9148-x&volume=26&issue=Suppl%201&pages=18-22&publication_year=2009&author=Atkins%2CMB generate monthly?
- What's the financial gain of https://doi.org/10.1111%2Fj.1749-6632.2003.tb06047.x?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12727638
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Dendritic%20cells%3A%20controllers%20of%20the%20immune%20system%20and%20a%20new%20promise%20for%20immunotherapy&journal=Ann%20N%20Y%20Acad%20Sci&doi=10.1111%2Fj.1749-6632.2003.tb06047.x&volume=987&pages=180-187&publication_year=2003&author=Banchereau%2CJ&author=Paczesny%2CS&author=Blanco%2CP&author=Bennett%2CL&author=Pascual%2CV&author=Fay%2CJ&author=Palucka%2CAK?
- Learn about the earnings of https://doi.org/10.1038%2Fnri2173
- How much does http://scholar.google.com/scholar_lookup?&title=Dendritic-cell%20immunotherapy%3A%20from%20ex%20vivo%20loading%20to%20in%20vivo%20targeting&journal=Nat%20Rev%20Immunol&doi=10.1038%2Fnri2173&volume=10&pages=790-802&publication_year=2007&author=Tacken%2CP&author=Vries%2CI&author=Torensma%2CR&author=Figdor%2CC&author=Tacken%2CPJ&author=Vries%2CIJM&author=Torensma%2CR&author=Figdor%2CCG gross monthly?
- Profit of https://doi.org/10.1097%2FCJI.0b013e318183db02
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18779746's total income per month
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Cytokine%20maturation%20followed%20by%20CD40L%20mRNA%20electroporation%20results%20in%20a%20clinically%20relevant%20dendritic%20cell%20product%20capable%20of%20inducing%20a%20potent%20proinflammatory%20CTL%20response&journal=J%20Immunother&doi=10.1097%2FCJI.0b013e318183db02&volume=31&issue=8&pages=731-741&publication_year=2008&author=Calderhead%2CDM&author=DeBenedette%2CMA&author=Ketteringham%2CH&author=Gamble%2CAH&author=Horvatinovich%2CJM&author=Tcherepanova%2CIY&author=Nicolette%2CCA&author=Healey%2CDG?
- Explore the financials of https://doi.org/10.4049%2Fjimmunol.181.8.5296
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18832685 is on a monthly basis
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Priming%20of%20a%20novel%20subset%20of%20CD28%2B%20rapidly%20expanding%20high-avidity%20effector%20memory%20CTL%20by%20post%20maturation%20electroporation-CD40L%20dendritic%20cells%20is%20IL-12%20dependent&journal=J%20Immunol&doi=10.4049%2Fjimmunol.181.8.5296&volume=181&issue=8&pages=5296-5305&publication_year=2008&author=DeBenedette%2CMA&author=Calderhead%2CDM&author=Ketteringham%2CH&author=Gamble%2CAH&author=Horvatinovich%2CJM&author=Tcherepanova%2CIY&author=Nicolette%2CCA&author=Healey%2CDG?
- How much money does https://doi.org/10.1097%2FCJI.0b013e3181fb651a make?
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21150712
- How much income does http://scholar.google.com/scholar_lookup?&title=Potency%20of%20mature%20CD40L%20RNA%20electroporated%20dendritic%20cells%20correlates%20with%20IL-12%20secretion%20by%20tracking%20multifunctional%20CD8%28%2B%29%2FCD28%28%2B%29%20cytotoxic%20T-cell%20responses%20in%20vitro&journal=J%20Immunother&doi=10.1097%2FCJI.0b013e3181fb651a&volume=34&issue=1&pages=45-57&publication_year=2011&author=DeBenedette%2CMA&author=Calderhead%2CDM&author=Tcherepanova%2CIY&author=Nicolette%2CCA&author=Healey%2CDG have?
- Financial intake of https://doi.org/10.4049%2Fjimmunol.164.10.5508
- What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10799919?
- What's http://scholar.google.com/scholar_lookup?&title=Human%20dendritic%20cells%20transfected%20with%20RNA%20encoding%20prostate-specific%20antigen%20stimulate%20prostate-specific%20CTL%20responses%20in%20vitro&journal=J%20Immunol&doi=10.4049%2Fjimmunol.164.10.5508&volume=164&issue=10&pages=5508-5514&publication_year=2000&author=Heiser%2CA&author=Dahm%2CP&author=Yancey%2CDR&author=Maurice%2CMA&author=Boczkowski%2CD&author=Nair%2CSK&author=Gilboa%2CE&author=Vieweg%2CJ's gross income?
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11249639?
- Find out how much http://scholar.google.com/scholar_lookup?&title=RNA%20transfected%20dendritic%20cells%20as%20cancer%20vaccines&journal=Curr%20Opin%20Mol%20Ther&volume=2&issue=2&pages=176-181&publication_year=2000&author=Mitchell%2CDA&author=Nair%2CSK earns monthly
- How much does https://doi.org/10.1172%2FJCI11405 net monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11067858 gross monthly?
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC301423 generate?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=RNA-transfected%20dendritic%20cells%20in%20cancer%20immunotherapy&journal=J%20Clin%20Invest&doi=10.1172%2FJCI11405&volume=106&issue=9&pages=1065-1069&publication_year=2000&author=Mitchell%2CDA&author=Nair%2CSK is on a monthly basis
- How much does https://doi.org/10.1172%2FJCI25947 gross monthly?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16308572
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288834 earn?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Enhancement%20of%20vaccine-mediated%20antitumor%20immunity%20in%20cancer%20patients%20after%20depletion%20of%20regulatory%20T%20cells&journal=J%20Clin%20Invest&doi=10.1172%2FJCI25947&volume=115&issue=12&pages=3623-3633&publication_year=2005&author=Dannull%2CJ&author=Su%2CZ&author=Rizzieri%2CD&author=Yang%2CBK&author=Coleman%2CD&author=Yancey%2CD&author=Zhang%2CA&author=Dahm%2CP&author=Chao%2CN&author=Gilboa%2CE&author=Vieweg%2CJ
- How much does https://doi.org/10.1158%2F1078-0432.CCR-08-1332 net monthly?
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19276286
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Sunitinib%20mediates%20reversal%20of%20myeloid-derived%20suppressor%20cell%20accumulation%20in%20renal%20cell%20carcinoma%20patients&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-08-1332&volume=15&issue=6&pages=2148-2157&publication_year=2009&author=Ko%2CJS&author=Zea%2CAH&author=Rini%2CBI&author=Ireland%2CJL&author=Elson%2CP&author=Cohen%2CP&author=Golshayan%2CA&author=Rayman%2CPA&author=Wood%2CL&author=Garcia%2CJ&author=Dreicer%2CR&author=Bukowski%2CR&author=Finke%2CJH?
- How much does https://doi.org/10.1158%2F1078-0432.CCR-07-5212 net monthly?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18927310
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Sunitinib%20reverses%20type-1%20immune%20suppression%20and%20decreases%20T-regulatory%20cells%20in%20renal%20cell%20carcinoma%20patients&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-07-5212&volume=14&issue=20&pages=6674-6682&publication_year=2008&author=Finke%2CJH&author=Rini%2CB&author=Ireland%2CJ&author=Rayman%2CP&author=Richmond%2CA&author=Golshayan%2CA&author=Wood%2CL&author=Elson%2CP&author=Garcia%2CJ&author=Dreicer%2CR&author=Bukowski%2CR
- How much does https://doi.org/10.1158%2F1078-0432.CCR-06-1924 make?
- How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17255301 have?
- How much income is http://scholar.google.com/scholar_lookup?&title=Reversal%20of%20tumor-mediated%20immunosuppression&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-06-1924&volume=13&issue=2%20Pt%202&pages=727s-732s&publication_year=2007&author=Vieweg%2CJ&author=Su%2CZ&author=Dahm%2CP&author=Kusmartsev%2CS earning monthly?
- What's the financial intake of https://doi.org/10.1158%2F1078-0432.CCR-08-0165?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19088044 generate?
- See how much http://scholar.google.com/scholar_lookup?&title=Reversal%20of%20myeloid%20cell-mediated%20immunosuppression%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-08-0165&volume=14&issue=24&pages=8270-8278&publication_year=2008&author=Kusmartsev%2CS&author=Su%2CZ&author=Heiser%2CA&author=Dannull%2CJ&author=Eruslanov%2CE&author=Kubler%2CH&author=Yancey%2CD&author=Dahm%2CP&author=Vieweg%2CJ makes per month
- What's the income of https://doi.org/10.1038%2Fbjc.2014.25?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24691425 rake in every month?
- How much profit is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992507 making per month?
- How much does http://scholar.google.com/scholar_lookup?&title=First-%2C%20second-%2C%20third-line%20therapy%20for%20mRCC%3A%20benchmarks%20for%20trial%20design%20from%20the%20IMDC&journal=Br%20J%20Cancer&doi=10.1038%2Fbjc.2014.25&volume=110&issue=8&pages=1917-1922&publication_year=2014&author=Ko%2CJJ&author=Choueiri%2CTK&author=Rini%2CBI&author=Lee%2CJL&author=Kroeger%2CN&author=Srinivas%2CS&author=Harshman%2CLC&author=Knox%2CJJ&author=Bjarnason%2CGA&author=MacKenzie%2CMJ&author=Wood%2CL&author=Vaishampayan%2CUN&author=Agarwal%2CN&author=Pal%2CSK&author=Tan%2CMH&author=Rha%2CSY&author=Yuasa%2CT&author=Donskov%2CF&author=Bamias%2CA&author=Heng%2CDY generate monthly?
- https://doi.org/10.1038%2Fbjc.2013.236 income
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23695024's revenue stream
- How much profit is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694236 making per month?
- How much does http://scholar.google.com/scholar_lookup?&title=Prognostic%20factors%20for%20survival%20in%201059%20patients%20treated%20with%20sunitinib%20for%20metastatic%20renal%20cell%20carcinoma&journal=Br%20J%20Cancer&doi=10.1038%2Fbjc.2013.236&volume=108&issue=12&pages=2470-2477&publication_year=2013&author=Motzer%2CRJ&author=Escudier%2CB&author=Bukowski%2CR&author=Rini%2CBI&author=Hutson%2CTE&author=Barrios%2CCH&author=Lin%2CX&author=Fly%2CK&author=Matczak%2CE&author=Gore%2CME pull in?
- Get to know what's the income of https://doi.org/10.1200%2FJCO.20.1.289
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11773181?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Interferon-alfa%20as%20a%20comparative%20treatment%20for%20clinical%20trials%20of%20new%20therapies%20against%20advanced%20renal%20cell%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.20.1.289&volume=20&issue=1&pages=289-296&publication_year=2002&author=Motzer%2CRJ&author=Bacik%2CJ&author=Murphy%2CBA&author=Russo%2CP&author=Mazumdar%2CM?
- How much does https://doi.org/10.1200%2FJCO.2008.21.4809 bring in each month?
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19826129
- How much does http://scholar.google.com/scholar_lookup?&title=Prognostic%20factors%20for%20overall%20survival%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma%20treated%20with%20vascular%20endothelial%20growth%20factor-targeted%20agents%3A%20results%20from%20a%20large%2C%20multicenter%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.21.4809&volume=27&issue=34&pages=5794-5799&publication_year=2009&author=Heng%2CDY&author=Xie%2CW&author=Regan%2CMM&author=Warren%2CMA&author=Golshayan%2CAR&author=Sahi%2CC&author=Eigl%2CBJ&author=Ruether%2CJD&author=Cheng%2CT&author=North%2CS&author=Venner%2CP&author=Knox%2CJJ&author=Chi%2CKN&author=Kollmannsberger%2CC&author=McDermott%2CDF&author=Oh%2CWK&author=Atkins%2CMB&author=Bukowski%2CRM&author=Rini%2CBI&author=Choueiri%2CTK earn?
- How much does https://doi.org/10.1056%2FNEJMoa065044 pull in monthly?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17215529's gross income?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Sunitinib%20versus%20interferon%20alfa%20in%20metastatic%20renal-cell%20carcinoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa065044&volume=356&issue=2&pages=115-124&publication_year=2007&author=Motzer%2CRJ&author=Hutson%2CTE&author=Tomczak%2CP&author=Michaelson%2CMD&author=Bukowski%2CRM&author=Rixe%2CO&author=Oudard%2CS&author=Negrier%2CS&author=Szczylik%2CC&author=Kim%2CST&author=Chen%2CI&author=Bycott%2CPW&author=Baum%2CCM&author=Figlin%2CRA?
- How much does https://doi.org/10.1200%2FJCO.2013.50.5305 pull in?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24297945 bring in?
- How much does http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20trial%20of%20temsirolimus%20and%20bevacizumab%20versus%20interferon%20alfa%20and%20bevacizumab%20in%20metastatic%20renal%20cell%20carcinoma%3A%20INTORACT%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2013.50.5305&volume=32&issue=8&pages=752-759&publication_year=2014&author=Rini%2CBI&author=Bellmunt%2CJ&author=Clancy%2CJ&author=Wang%2CK&author=Niethammer%2CAG&author=Hariharan%2CS&author=Escudier%2CB pull in monthly?
- Learn how profitable https://doi.org/10.3816%2FCGC.2009.n.004 is on a monthly basis
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19213664?
- How much profit is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740755 making per month?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Phase%20I%20study%20combining%20treatment%20with%20temsirolimus%20and%20sunitinib%20malate%20in%20patients%20with%20advanced%20renal%20cell%20carcinoma&journal=Clin%20Genitourin%20Cancer&doi=10.3816%2FCGC.2009.n.004&volume=7&issue=1&pages=24-27&publication_year=2009&author=Patel%2CPH&author=Senico%2CPL&author=Curiel%2CRE&author=Motzer%2CRJ
- How much does https://doi.org/10.1002%2Fcncr.26429 net monthly?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21898375?
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Phase%201%20trial%20of%20everolimus%20plus%20sunitinib%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma&journal=Cancer&doi=10.1002%2Fcncr.26429&volume=118&issue=7&pages=1868-1876&publication_year=2012&author=Molina%2CAM&author=Feldman%2CDR&author=Voss%2CMH&author=Ginsberg%2CMS&author=Baum%2CMS&author=Brocks%2CDR&author=Fischer%2CPM&author=Trinos%2CMJ&author=Patil%2CS&author=Motzer%2CRJ
- How much does https://doi.org/10.1200%2FJCO.2008.19.0108 pull in?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19224847?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655420?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%20bevacizumab%20plus%20escalated%20doses%20of%20sunitinib%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.19.0108&volume=27&issue=9&pages=1432-1439&publication_year=2009&author=Feldman%2CDR&author=Baum%2CMS&author=Ginsberg%2CMS&author=Hassoun%2CH&author=Flombaum%2CCD&author=Velasco%2CS&author=Fischer%2CP&author=Ronnen%2CE&author=Ishill%2CN&author=Patil%2CS&author=Motzer%2CRJ
- https://doi.org/10.1200%2FJCO.2008.20.1293's financial summary
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19487381 income
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646307?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Overall%20survival%20and%20updated%20results%20for%20sunitinib%20compared%20with%20interferon%20alfa%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.20.1293&volume=27&issue=22&pages=3584-3590&publication_year=2009&author=Motzer%2CRJ&author=Hutson%2CTE&author=Tomczak%2CP&author=Michaelson%2CMD&author=Bukowski%2CRM&author=Oudard%2CS&author=Negrier%2CS&author=Szczylik%2CC&author=Pili%2CR&author=Bjarnason%2CGA&author=Garcia-del-Muro%2CX&author=Sosman%2CJA&author=Solska%2CE&author=Wilding%2CG&author=Thompson%2CJA&author=Kim%2CST&author=Chen%2CI&author=Huang%2CX&author=Figlin%2CRA
- What's the total monthly financial gain of https://doi.org/10.1200%2FJCO.2011.36.4133?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22430274?
- Get to know http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20II%20trial%20of%20sunitinib%20on%20an%20intermittent%20versus%20continuous%20dosing%20schedule%20as%20first-line%20therapy%20for%20advanced%20renal%20cell%20carcinoma&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2011.36.4133&volume=30&issue=12&pages=1371-1377&publication_year=2012&author=Motzer%2CRJ&author=Hutson%2CTE&author=Olsen%2CMR&author=Hudes%2CGR&author=Burke%2CJM&author=Edenfield%2CWJ&author=Wilding%2CG&author=Agarwal%2CN&author=Thompson%2CJA&author=Cella%2CD&author=Bello%2CA&author=Korytowsky%2CB&author=Yuan%2CJ&author=Valota%2CO&author=Martell%2CB&author=Hariharan%2CS&author=Figlin%2CRA's earnings
- Profit of https://doi.org/10.2214%2FAJR.11.7483
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22451534
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369700
- How much profit does http://scholar.google.com/scholar_lookup?&title=Personalized%20tumor%20response%20assessment%20in%20the%20era%20of%20molecular%20medicine%3A%20cancer-specific%20and%20therapy-specific%20response%20criteria%20to%20complement%20pitfalls%20of%20RECIST&journal=AJR%20Am%20J%20Roentgenol&doi=10.2214%2FAJR.11.7483&volume=198&issue=4&pages=737-745&publication_year=2012&author=Nishino%2CM&author=Jagannathan%2CJP&author=Krajewski%2CKM&author=O%27Regan%2CK&author=Hatabu%2CH&author=Shapiro%2CG&author=Ramaiya%2CNH make?
- What is the monthly revenue of https://doi.org/10.1056%2FNEJMoa1003466?
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20525992?
- How much profit is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297 making per month?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1003466&volume=363&issue=8&pages=711-723&publication_year=2010&author=Hodi%2CFS&author=O%27Day%2CSJ&author=McDermott%2CDF&author=Weber%2CRW&author=Sosman%2CJA&author=Haanen%2CJB&author=Gonzalez%2CR&author=Robert%2CC&author=Schadendorf%2CD&author=Hassel%2CJC&author=Akerley%2CW&author=Eertwegh%2CAJ&author=Lutzky%2CJ&author=Lorigan%2CP&author=Vaubel%2CJM&author=Linette%2CGP&author=Hogg%2CD&author=Ottensmeier%2CCH&author=Lebbe%2CC&author=Peschel%2CC&author=Quirt%2CI&author=Clark%2CJI&author=Wolchok%2CJD&author=Weber%2CJS&author=Tian%2CJ&author=Yellin%2CMJ&author=Nichol%2CGM&author=Hoos%2CA&author=Urba%2CWJ
- What are the total earnings of https://doi.org/10.1038%2Fni.2079?
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21804558
- How much income is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388550 earning monthly?
- How much profit does http://scholar.google.com/scholar_lookup?&title=Autocrine%20IL-2%20is%20required%20for%20secondary%20population%20expansion%20of%20CD8%28%2B%29%20memory%20T%20cells&journal=Nat%20Immunol&doi=10.1038%2Fni.2079&volume=12&issue=9&pages=908-913&publication_year=2011&author=Feau%2CS&author=Arens%2CR&author=Togher%2CS&author=Schoenberger%2CSP generate?
- What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17352228?
- How much does http://scholar.google.com/scholar_lookup?&title=Renal%20cell%20carcinoma-induced%20immunosuppression%3A%20an%20immunophenotypic%20study%20of%20lymphocyte%20subpopulations%20and%20circulating%20dendritic%20cells&journal=Anticancer%20Res&volume=27&issue=1A&pages=165-173&publication_year=2007&author=Porta%2CC&author=Bonomi%2CL&author=Lillaz%2CB&author=Paglino%2CC&author=Rovati%2CB&author=Imarisio%2CI&author=Morbini%2CP&author=Villa%2CC&author=Danova%2CM&author=Mensi%2CM&author=Rovereto%2CB gross monthly?
- How much profit does https://doi.org/10.7150%2Fjca.5046 generate?
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23386903
- How much does http://scholar.google.com/scholar_lookup?&title=Dendritic%20cells%20in%20the%20cancer%20microenvironment&journal=J%20Cancer&doi=10.7150%2Fjca.5046&volume=4&issue=1&pages=36-44&publication_year=2013&author=Ma%2CY&author=Shurin%2CGV&author=Peiyuan%2CZ&author=Shurin%2CMR gross monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16819631 net monthly?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=CD4%20regulatory%20T%20cells%20in%20human%20cancer%20pathogenesis&journal=Cancer%20Immunol%20Immunother&doi=10.1007%2Fs00262-006-0194-y&volume=56&issue=3&pages=271-285&publication_year=2007&author=Knutson%2CKL&author=Disis%2CML&author=Salazar%2CLG?
- https://doi.org/10.1016%2FS0264-410X%2802%2900382-1's financial summary
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12477423 make?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=A%20clinical%20grade%20cocktail%20of%20cytokines%20and%20PGE2%20results%20in%20uniform%20maturation%20of%20human%20monocyte-derived%20dendritic%20cells%3A%20implications%20for%20immunotherapy&journal=Vaccine&doi=10.1016%2FS0264-410X%2802%2900382-1&volume=20&issue=Suppl%204&pages=A8-A22&publication_year=2002&author=Lee%2CAW&author=Truong%2CT&author=Bickham%2CK&author=Fonteneau%2CJF&author=Larsson%2CM&author=Silva%2CI&author=Somersan%2CS&author=Thomas%2CEK&author=Bhardwaj%2CN generate?
- How much does https://doi.org/10.1200%2FJCO.2008.19.6147 pull in monthly?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19858404?
- How much does http://scholar.google.com/scholar_lookup?&title=In%20situ%20cytotoxic%20and%20memory%20T%20cells%20predict%20outcome%20in%20patients%20with%20early-stage%20colorectal%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.19.6147&volume=27&issue=35&pages=5944-5951&publication_year=2009&author=Pages%2CF&author=Kirilovsky%2CA&author=Mlecnik%2CB&author=Asslaber%2CM&author=Tosolini%2CM&author=Bindea%2CG&author=Lagorce%2CC&author=Wind%2CP&author=Marliot%2CF&author=Bruneval%2CP&author=Zatloukal%2CK&author=Trajanoski%2CZ&author=Berger%2CA&author=Fridman%2CWH&author=Galon%2CJ pull in monthly?
- What's the income generated by https://doi.org/10.1111%2Fj.1399-0039.2008.01088.x each month?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18627571
- http://scholar.google.com/scholar_lookup?&title=Memory%20T%20cells%20in%20cancer%20immunotherapy%3A%20which%20CD8%20T-cell%20population%20provides%20the%20best%20protection%20against%20tumours%3F&journal=Tissue%20Antigens&doi=10.1111%2Fj.1399-0039.2008.01088.x&volume=72&issue=3&pages=187-194&publication_year=2008&author=Perret%2CR&author=Ronchese%2CF income
- What's the financial outcome of https://doi.org/10.1111%2Fj.0105-2896.2006.00391.x?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16824130 net monthly?
- What's the income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1501075?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=CD8%2B%20T-cell%20memory%20in%20tumor%20immunology%20and%20immunotherapy&journal=Immunol%20Rev&doi=10.1111%2Fj.0105-2896.2006.00391.x&volume=211&pages=214-224&publication_year=2006&author=Klebanoff%2CCA&author=Gattinoni%2CL&author=Restifo%2CNP generate?
- https://doi.org/10.1634%2Ftheoncologist.2010-0263's total income per month
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21490127
- How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228204 generate?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Sunitinib%20in%20metastatic%20renal%20cell%20carcinoma%3A%20recommendations%20for%20management%20of%20noncardiovascular%20toxicities&journal=Oncologist&doi=10.1634%2Ftheoncologist.2010-0263&volume=16&issue=5&pages=543-553&publication_year=2011&author=Kollmannsberger%2CC&author=Bjarnason%2CG&author=Burnett%2CP&author=Creel%2CP&author=Davis%2CM&author=Dawson%2CN&author=Feldman%2CD&author=George%2CS&author=Hershman%2CJ&author=Lechner%2CT&author=Potter%2CA&author=Raymond%2CE&author=Treister%2CN&author=Wood%2CL&author=Wu%2CS&author=Bukowski%2CR?
- What's https://doi.org/10.1200%2FJCO.2011.40.3824's gross income?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22802313?
- How much does http://scholar.google.com/scholar_lookup?&title=The%20price%20we%20pay%20for%20progress%3A%20A%20meta-analysis%20of%20harms%20of%20newly%20approved%20anticancer%20drugs&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2011.40.3824&volume=30&pages=3012-3019&publication_year=2012&author=Niraula%2CS&author=Seruga%2CB&author=Ocana%2CA&author=Shao%2CT&author=Goldstein%2CR&author=Tannock%2CIF&author=Amir%2CE earn?
- How much money does https://doi.org/10.1093%2Fjnci%2F92.3.205 make?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10655437 rake in every month?
- http://scholar.google.com/scholar_lookup?&title=New%20guidelines%20to%20evaluate%20the%20response%20to%20treatment%20in%20solid%20tumors.%20European%20Organization%20for%20Research%20and%20Treatment%20of%20Cancer%2C%20National%20Cancer%20Institute%20of%20the%20United%20States%2C%20National%20Cancer%20Institute%20of%20Canada&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2F92.3.205&volume=92&issue=3&pages=205-216&publication_year=2000&author=Therasse%2CP&author=Arbuck%2CSG&author=Eisenhauer%2CEA&author=Wanders%2CJ&author=Kaplan%2CRS&author=Rubinstein%2CL&author=Verweij%2CJ&author=Glabbeke%2CM&author=Oosterom%2CAT&author=Christian%2CMC&author=Gwyther%2CSG income
- What's the monthly income of https://doi.org/10.1038%2Fmtna.2013.18?
- Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23653155 earns monthly
- How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817939 generate?
- Profit of http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20RNA%20Amplification%20Methods%20to%20Improve%20DC%20Immunotherapy%20Antigen%20Presentation%20and%20Immune%20Response&journal=Mol%20Ther%20Nucleic%20Acids&doi=10.1038%2Fmtna.2013.18&volume=2&publication_year=2013&author=Slagter-Jager%2CJG&author=Raney%2CA&author=Lewis%2CWE&author=Debenedette%2CMA&author=Nicolette%2CCA&author=Tcherepanova%2CIY
- What's the revenue for https://doi.org/10.1371%2Fjournal.pone.0001489?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18231576 earn?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211536 earn?
- Get to know http://scholar.google.com/scholar_lookup?&title=Multiplex%20RT-PCR%20amplification%20of%20HIV%20genes%20to%20create%20a%20completely%20autologous%20DC-based%20immunotherapy%20for%20the%20treatment%20of%20HIV%20infection&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0001489&volume=3&issue=1&publication_year=2008&author=Tcherepanova%2CI&author=Harris%2CJ&author=Starr%2CA&author=Cleveland%2CJ&author=Ketteringham%2CH&author=Calderhead%2CD&author=Horvatinovich%2CJ&author=Healey%2CD&author=Nicolette%2CCA's earnings
- Learn how profitable https://citation-needed.springer.com/v2/references/10.1186/s40425-015-0055-3?format=refman&flavour=references is on a monthly basis
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Asim%20Amin produce monthly?
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Asim%20Amin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Arkadiusz%20Z%20Dudek
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Arkadiusz%20Z%20Dudek%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Theodore%20F%20Logan?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Theodore%20F%20Logan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Raymond%20S%20Lance
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Raymond%20S%20Lance%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Get to know https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jeffrey%20M%20Holzbeierlein's earnings
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jeffrey%20M%20Holzbeierlein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jennifer%20J%20Knox
- Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jennifer%20J%20Knox%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Viraj%20A%20Master's financial summary
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Viraj%20A%20Master%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sumanta%20K%20Pal pull in?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sumanta%20K%20Pal%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en income
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wilson%20H%20Miller
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wilson%20H%20Miller%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en income
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lawrence%20I%20Karsh?
- Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lawrence%20I%20Karsh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Irina%20Y%20Tcherepanova?
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Irina%20Y%20Tcherepanova%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20A%20DeBenedette gross monthly?
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20A%20DeBenedette%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=W%20Lee%20Williams?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22W%20Lee%20Williams%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Douglas%20C%20Plessinger produce monthly?
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Douglas%20C%20Plessinger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Charles%20A%20Nicolette
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Charles%20A%20Nicolette%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Robert%20A%20Figlin
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Robert%20A%20Figlin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit is https://crossmark.crossref.org/dialog/?doi=10.1186/s40425-015-0055-3 making per month?
- What's the financial intake of https://citation-needed.springer.com/v2/references/10.1186/s40425-015-0055-3?format=refman&flavour=citation?
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral bring in each month?
- How much money does https://www.springernature.com/gp/products make?
- What is the monthly revenue of https://www.springernature.com/gp/librarians?
- What are the total earnings of https://www.springernature.com/gp/societies?
- Financial intake of https://www.springernature.com/gp/partners
- How much revenue does https://www.springer.com/ bring in?
- What's the revenue for https://www.nature.com/?
- How much profit does https://www.biomedcentral.com/ make?
- Explore the financials of https://www.palgrave.com/
- How much revenue does https://www.apress.com/ bring in?
- Revenue of https://www.springernature.com/gp/legal/ccpa
- How much profit does https://www.springernature.com/gp/info/accessibility make?
- What's the income of https://support.springernature.com/en/support/home?
- How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations bring in each month?
- What's the financial outcome of https://www.springernature.com/?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref